2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Molecular Testing, Omics Technologies, Bioinformatics, Computational Biology, Emerging Technologies, Gene Editing, Profiling, Treatment Considerations, Drug Development, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Immunotherapy, Artificial Intelligence (AI), Machine Learning, Biological Processes, Pathogenesis, Genomics, Immune Mechanism, Metabolism, Molecular Biology, Clinical Practice (Health Services and Quality), Practice Models, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Myeloid Malignancies, Acute Myeloid Malignancies, Measurable Residual Disease, ALL, Research, Fundamental Science, Translational Research, Clinical Research, Epidemiology, Real-World Evidence, Study Population, Human, Adult, Elderly, Pediatric, Young Adult, Animal Model
PAPER

1569 Genomic profiling informs early clinical management of pediatric patients with leukemia from Northeast Centers

Sabrina Testa, MD, Trevor Coles, MD2, Catherine F. Seaman3, Nathan Hope4, Asmani A. Adhav, MS5, Victoria B. Koch, BS6, Shanna L. Richard7, Yael Flamand, MS8, Jessica L. Geaney, MD9, Natalie S. Bezler, MD10, Angela M. Ricci, MD11, Jennifer J. G. Welch, MD12, Sei-Gyung K. Sze, MD13, Jessica L. Heath, MD14, Melissa A. Burns, MD15, Franziska Wachter, MD16, Wallace A. Bourgeois, MD17, Jonathan D. Paolino, MD18, Lewis B. Silverman, MD19, Marian H. Harris, MD, PhD20, Harrison K. Tsai, MD21, Kayla V. Hamilton22, Andrew E. Place, MD, PhD23, Jessica A. Pollard I, MD24, Yana Pikman, MD25
1 Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy, University of Parma, Parma, Italy
2 Golisano Children’s Hospital at UVM Health, Burlington, Vermont, United States
3 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
4 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
5 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
6 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
7 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
8 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
9 Albany Medical Center, Albany, New York, United States
10 Connecticut Children’s Medical Center; The University of Connecticut School of Medicine, Hartford, Connecticut, United States
11 Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States
12 Alpert School of Medicine, Brown University, Providence, Rhode Island, United States
13 Maine Medical Center, Portland, Maine, United States
14 Golisano Children’s Hospital at UVM Health, Burlington, Vermont, United States
15 Boston Children's Hospital, Boston, Massachusetts, United States, Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States
16 Boston Children's Hospital, Boston, Massachusetts, United States, Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States
17 Boston Children's Hospital, Boston, Massachusetts, United States, Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States
18 Boston Children's Hospital, Boston, Massachusetts, United States, Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States
19 Columbia University Irving Medical Center, New York, New York, United States
20 Boston Children's Hospital, Boston, Massachusetts, United States
21 Boston Children's Hospital, Boston, Massachusetts, United States
22 Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, Massachusetts, United States
23 Boston Children's Hospital, Boston, Massachusetts, United States, Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States
24 Boston Children's Hospital, Boston, Massachusetts, United States, Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States
25 Boston Children's Hospital, Boston, Massachusetts, United States, Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States

Introduction

Disease characterization in pediatric leukemia increasingly relies on advanced sequencing technologies, yet implementation remains limited outside tertiary centers. Our Regional Leukemia Genomics Study expanded access to genome profiling and multidisciplinary tumor board review to pediatric oncology centers in the Northeast United States through a regional precision medicine consortium. We report the clinical impact of this study on the first 150 patients enrolled.

Study design

Six institutions across New England and New York enrolled 150 pediatric patients with newly diagnosed or relapsed leukemia between November 2021 and July 2025. Diagnostic samples underwent centralized targeted DNA (Rapid Heme Panel, RHP) and RNA sequencing at Dana-Farber Cancer Institute/Boston Children’s Hospital. Results were returned to treating clinicians, with selected cases reviewed at monthly tumor boards involving participating centers and experts in leukemia.

Results

92% of patients in our cohort had a newly diagnosed leukemia: B-cell acute lymphoblastic leukemia (B-ALL) was the most frequent (71%), followed by myeloid malignancies (17%) and T-cell ALL (T-ALL, 12%). Median age at enrolment was 9 years (range 0-22) and 60% were male. Integrated genomic profiling identified 338 sequence variants in 124 patients (83%) and 76 fusions in 75 patients (50%). Overall, 251/338 alterations (74%) were classified as pathogenic, including 209 (83%) with oncogenic annotation in OncoKB. RAS/MAPK signaling alterations were the most common pathogenic events (89/251, 35%). Eighteen patients (12%) lacked identifiable driver alterations.

RNA-based fusion panel detected 19 cryptic rearrangements (19/76, 25%) and resolved fusion partners in 9 cases (9/76, 12%). We identified three previously undescribed fusions (NR3C1::PAG1, KMT2A::BCAT1, SET::MLLT10) and 7 rare rearrangements (ETV6::LMBR1, PAX5::FBRLS1, RNF38::PAX5, KAT6A::NCOA2, KMT2A::AFDN, KMT2A::USP2, IKZF2::NOTCH1) carrying diagnostic, prognostic or therapeutic implications. KMT2A::USP2 revised risk classification and upstaged treatment in one non-infant patient with acute myeloid leukemia (AML). Cryptic IKZF1 deletions were uncovered in nine patients and co-occurrence with ERG-alt transcripts supported the diagnosis of DUX4-rearranged B-ALL in three cases. An intragenic IKZF1 deletion refined prognosis in the NR3C1::PAG1-rearranged B-ALL, while concurrent IKZF1 alteration and CDKN2A deletion defined an IKZF1plus ALL. Three, otherwise cryptic, subtype defining, PAX5 P80R alterations were also identified.

Genomic findings raised suspicion for germline cancer predisposition in 17 patients (11%) across 12 predisposition genes (TP53, RUNX1, GATA2, ETV6, PAX5, PTPN11, NF1, DDX41, IKZF1, ERG, ATRX, and TERT). Repeat RHP testing at remission demonstrated persistence of a TP53 R273C variant (VAF 34.8% vs. 52.8% at diagnosis) and one PTPN11 E258K variant (VAF 42.7%) associated with Noonan syndrome was confirmed as germline. 

Cryptic actionable fusions prompted initiation of revumenib, imatinib and FOLR1-targeted therapy in patients with KMT2A::BCAT1 acute leukemia of ambiguous lineage, relapsed NUP214::ABL1 B-ALL, and CBFA2T3::GLIS2 AML, respectively. In refractory diseases, a FLT3-ITD/NUP98-rearranged AML case was switched from gilteritinib to venetoclax, while an IL7R p.L242delinsFGPPC variant supported ruxolitinib treatment in high-risk B-ALL.

Paired diagnosis-relapse samples were available for seven patients (B-ALL n=5, AML n=2). Three acquired TP53 mutations at relapse (43%), and one near-haploid B-ALL underwent lineage switch following blinatumomab treatment after first relapse. 

Conclusions

Genome profiling uncovered clinically relevant alterations beyond conventional testing in pediatric patients with leukemia. Rapid turnaround of results and expert review of complex cases at smaller oncology centers informed diagnosis, risk stratification and targeted treatment selection for patients with aggressive diseases who otherwise have limited therapeutic options. Profiling also raised suspicion for underlying germline cancer predisposition and facilitated referral for genetic counseling and testing. This real-world regional precision medicine model supports the integration of genomic profiling into standard frontline care for pediatric patients with leukemia and provides a scalable framework for future genomics-guided trials and therapeutic discovery.

Sabrina Testa, MD: No relevant conflicts of interest to declare.